환인제약

016580KOSPI의약품 제조업

55.0 / 100

Reference Date: 2026-04-13

Financial Score26.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hwanin Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, with psychiatric and neurological drugs accounting for over 80% of total revenue. According to the 2024 IMS DATA, the company holds the top position in the domestic psychotropic drug market. Its affiliated subsidiaries, Ambrobi&F and Asyu, focus on pharmaceutical R&D and comprehensive distribution, respectively.

Number of Employees

671people

Average Salary

75.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.10Industry Average 14.805.0Point

In line with industry avg

PBR

0.46Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

3.41Industry Average 4.422.5Point

Below industry avg

Debt Ratio

0.33Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼34.1% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 6.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 10,370Won52-week high 13,13052-week low 10,030

1-month return3.0Point

1m 0.19% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업가치제고계획(자율공시)2026-03-23
Neutral정기주주총회결과2026-03-20
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-20